Tibaut Miha, Caprnda Martin, Kubatka Peter, Sinkovič Andreja, Valentova Vanda, Filipova Slavomira, Gazdikova Katarina, Gaspar Ludovit, Mozos Ioana, Egom Emmanuel E, Rodrigo Luis, Kruzliak Peter, Petrovic Daniel
General Hospital Murska Sobota, Murska Sobota, Slovenia.
1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Heart Lung Circ. 2019 May;28(5):667-677. doi: 10.1016/j.hlc.2018.06.1057. Epub 2018 Oct 4.
Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.
动脉粥样硬化是全球发病和死亡的主要原因。考虑到治疗效果，几种风险评分被用于区分心血管（CV）事件低、中或高风险的个体。然而，对于中度风险个体的最佳管理方法仍不明确，因此，人们正在寻找新的生物标志物，以帮助将他们重新分类为低风险或高风险。本叙述性综述分为两部分。在第一部分中，我们总结了目前关于动脉粥样硬化血清（血清学）生物标志物的知识。在新的生物标志物中，高敏C反应蛋白（hsCRP）在慢性情况下已成为最有前景的指标，其他指标还需要进一步的临床研究。然而，血清生物标志物的组合似乎比单一生物标志物在风险分层方面提供了更多信息。在第二部分中，我们将探讨动脉粥样硬化的遗传和影像学标志物，以及与风险预测相关的其他进展。
